NOVARTIS AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89.91 CHF | -0.52% |
|
-3.59% | +5.95% |
| 12:46pm | Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy | MT |
| 08:23am | Novartis: positive data for Fabhalta in HPN | CF |
Main competitors
| 1m. EPS revision | 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Divergence of Estimates | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
| 19 | |||||||||
| 27 | |||||||||
| 23 | |||||||||
| 23 | |||||||||
| 28 | |||||||||
| 25 | |||||||||
| 18 | |||||||||
| 19 | |||||||||
| 26 | |||||||||
| 23 | |||||||||
| 21 | |||||||||
| 21 | |||||||||
| 27 | |||||||||
| 15 | |||||||||
| 18 | |||||||||
| 18 | |||||||||
| 17 | |||||||||
| 17 | |||||||||
| 17 | |||||||||
| Average | 21 | ||||||||
| Weighted average by Cap. | 23 |
- Stock Market
- Equities
- NOVN Stock
- Sector Novartis AG
- Sector revisions